Assessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant naltrexone in the treatment of heroin dependence

Clinical Trials

Volumn 10, Issue 1, 2013, Pages 170-180

  Kelty, Erin ^a,b   Ngo, Hanh ^a   Hulse, Gary ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Fresh Start Recovery Programme   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; PLACEBO;

ANOREXIA; ARTICLE; AUSTRALIA; DATA COLLECTION METHOD; DATA PROCESSING; DEPRESSION; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; EMERGENCY WARD; FATIGUE; FOLLOW UP; HEADACHE; HEALTH DATA LINKAGE SYSTEM; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HUMAN; MENTAL HEALTH; NAUSEA; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SLEEP DISORDER; STOMACH DISEASE; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA COLLECTION; DRUG IMPLANTS; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; NALTREXONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF REPORT;

EID: 84872860667     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512467237     Document Type: Article

References (19)

1. Weissman JS, Schneider EC, Weingart SN, et al. Comparing patient-reported hospital adverse events with medical record review: Do patients know something that hospitals do not?. Ann Intern Med. 2008 ; 149 (2). 100-10
2. Sims ACP. Importance of a high tracing-rate in long-term medical follow-up studies. Lancet. 1973 ; 302 (7826). 433-35
3. Digiusto E, Panjari M, Gibson A, Rea F. Follow up difficulty: Correlates and relationships with outcome in heroin dependence treatment in the NEPOD study. Addict Behav. 2006 ; 31 (7). 1201-10
4. World drug report 2009. Vienna: United Nations Office on Drugs and Crime ; 2009 :
5. McKeganey N, Bloor M, Robertson M, et al. Abstinence and drug abuse treatment: Results from the drug outcome research in Scotland study. Drug-Educ Prev Polic. 2006 ; 13 (6). 537-50
6. Comer SD, Sullivan MA, Hulse GK. Sustained release naltrexone: Novel treatment for opioid dependence. Expert Opin Investig Drugs. 2007 ; 16 (8). 1285-94
7. Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984 ; 10 (2). 249-66
8. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: Randomized controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009 ; 66 (10). 1108-15
9. Hulse GK, Ngo HTT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psychiatry. 2010 ; 68 (3). 296-302
10. The Australian Clinical Trial Handbook. Australia: Department of Health and Aging, Australian Government, Canberra, ACT ; 2006 :
11. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Australia: Commonwealth Department of Health and Aged Care, Canberra, ACT ; 2000 :
12. Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95). Australia: Commonwealth Department of Health and Aging, Canberra, ACT ; 2000 :
13. Brameld KJ, Holman D, Thomas M, Bass J. Use of a state data bank to measure incidence and prevalence of chronic disease: End-stage renal failure. Am J Kidney Dis. 1999 ; 34 (6). 1033-39
14. Hulse GK, English DR, Milne E, Holman CD. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999 ; 94 (2). 221-29
15. Ngo HTT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance of naltrexone implantation. Arch Gen Psychiatry. 2008 ; 65 (4). 457-65
16. Darke S. Self report among injecting drug users: A review. Drug Alcohol Depend. 1998 ; 51: 253-63
17. Murray DW, Britton AR, Bulstrode CJK. Loss to follow up matters. J Bone Joint Surg Br. 1997 ; 79 (B). 254-57
18. Ndiaye B, Ould-Kaci K, Salleron J. Characteristics and outcomes in HIV-infected patients who return to care after being loss to follow-up. et al AIDS. 2009 ; 23 (13). 1786-89
19. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005 ; 23 (1). 77-91